- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Turn Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| TURN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 01.06. | Turn Therapeutics: Positive Studiendaten zu Ekzem-Medikament treiben Aktie an | 3 | Investing.com Deutsch | ||
| 01.06. | Turn Therapeutics reports interim phase 2 data for eczema drug | 2 | Investing.com | ||
| 27.05. | Turn Therapeutics publishes GX-03 dermatitis study results | 1 | Investing.com | ||
| 27.05. | Turn Therapeutics Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 19.05. | Turn Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 18.05. | Turn Therapeutics appoints former FDA chief Stephen Hahn | 3 | Investing.com | ||
| 11.05. | Turn Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 11.05. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 31.03. | Turn Therapeutics Inc. GAAP EPS of -$0.12 beats by $0.01 | 3 | Seeking Alpha | ||
| 31.03. | Turn Therapeutics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 31.03. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.03. | Turn Therapeutics: $25 Million Financing Secured By Dermatology Biotechnology Company | 3 | pulse2.com | ||
| 24.03. | Turn Therapeutics secures up to $25M in financing from Avenue Capital Group | 1 | Seeking Alpha | ||
| 24.03. | Turn Therapeutics secures $25M loan facility from Avenue Capital | 1 | Investing.com | ||
| 24.03. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.03. | Turn Therapeutics erhält Kreditfazilität von bis zu 25 Millionen US-Dollar von Avenue Capital | 3 | Investing.com Deutsch | ||
| 17.02. | Turn Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.02. | Turn Therapeutics Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Turn Therapeutics treibt Dermatitis-Studie voran und erweitert Pipeline | 7 | Investing.com Deutsch |
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TILRAY BRANDS | 3,875 | +1,04 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 03.07.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| VIATRIS | 14,196 | -0,74 % | VTRS or DHR: Which Is the Better Value Stock Right Now? | ||
| SYNBIOTIC | 1,140 | -0,52 % | SYNBIOTIC SE: Portfoliobereinigung setzt die Basis neu; Kursziel gesenkt, bleibt jedoch Spek. KAUFEN | SYNBIOTIC stellt sein Portfolio neu auf, nachdem Hempro International, HANF FARM und Hemp Factory in Richtung Liquidation und/oder Insolvenz gehen, bedingt durch einen starken Rückgang der Nachfrage... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 11,225 | -1,54 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces First Patient Enrolled in Phase 2 HORIZON Study of TNX-102 SL for the Treatment of Major Depressive Disorder (MDD) | HORIZON is a potentially pivotal, randomized, double-blind, placebo-controlled Phase 2 study evaluating TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg as a first-line monotherapy in adults... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,300 | -4,64 % | DesignRush: Brooke Sellas Joins DesignRush Podcast on Social Media's Revenue Risk | Miami, Florida--(Newsfile Corp. - June 23, 2026) - The latest episode of the DesignRush Podcast features Brooke Sellas, founder and CEO of B Squared Media. The episode explores why companies risk... ► Artikel lesen | |
| XORTX THERAPEUTICS | 1,787 | -3,06 % | XORTX Therapeutics Inc.: XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange | CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the "Company") (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused... ► Artikel lesen | |
| SOLIGENIX | 0,368 | +0,05 % | SOLIGENIX, INC.: Soligenix Announces Recent Updates and First Quarter 2026 Financial Results | PRINCETON, N.J., May 8, 2026 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing... ► Artikel lesen | |
| TALPHERA | 1,250 | +5,04 % | Talphera, Inc.: Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update | NEPHRO CRRT clinical study expected to be completed this year
Cash and investments of $21.1 million at March 31, 2026
Conference call and webcast to be held on Wednesday... ► Artikel lesen | |
| SAVARA | 5,250 | -3,99 % | Savara Inc.: Savara Announces the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) Has Accepted the MOLBREEVI* Marketing Authorisation Application (MAA) for Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP) | -- MHRA's Acceptance Follows Acceptance/Validation of MOLBREEVI Biologics License Application (BLA) and MAA in Autoimmune PAP by the U.S. Food and Drug Administration (FDA) and the European Medicines... ► Artikel lesen | |
| SCYNEXIS | 4,330 | -5,15 % | XFRA 135: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILSCYNEXIS INC. DL... ► Artikel lesen | |
| THERIVA BIOLOGICS | 0,243 | +4,75 % | Theriva Biologics, Inc.: Theriva Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal | - VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial -
- Study builds on positive clinical data from the recent... ► Artikel lesen | |
| WAVE LIFE SCIENCES | 5,100 | -8,11 % | Wave Life Sciences Ltd.: Wave Life Sciences Announces Singapore Court Hearing, to be held on July 14, 2026 to Approve Scheme of Arrangement for Redomiciliation | CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential... ► Artikel lesen | |
| TUHURA BIOSCIENCES | 2,140 | +3,88 % | TuHURA Biosciences, Inc./NV - 8-K, Current Report | ||
| THERAPEUTICSMD | 1,650 | 0,00 % | TherapeuticsMD, Inc. - 8-K, Current Report | ||
| SKYE BIOSCIENCE | 0,565 | 0,00 % | Skye Bioscience, Inc.: Skye Announces Cohort Review Committee Approved Opening of Cohort 2 Based on Favorable Safety Data from First Four Participants Treated in Cohort 1 | SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic... ► Artikel lesen |
Das Unternehmen TURN THERAPEUTICS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 9,470 Euro und damit +7,49 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TURN THERAPEUTICS INC finden Sie auf Wallstreet Online.